Document is current
Any future updates will be listed below
-
Authors
Van Laethem, Delphine
Costers, Lars
Miravalle, Augusto
Alvarez, Enrique
Myers, Bennett
Boster, Aaron
Al Halawani, Hanan
Dewil, Maarten
Cambron, Melissa
Grothe, Matthias
Denissen, Stijn
Bartz, Rebecca
Sima, Diana
Ribbens, Annemie
Smeets, Dirk
Nagels, Guy
-
Funding
Funding for this research was provided by:
CLAIMS project, funded by the Innovative Health Initiative Joint Undertaking (101112153)
CLAIMS project, funded by the Innovative Health Initiative Joint Undertaking (101112153)
CLAIMS project, funded by the Innovative Health Initiative Joint Undertaking (101112153)
CLAIMS project, funded by the Innovative Health Initiative Joint Undertaking (101112153)
CLAIMS project, funded by the Innovative Health Initiative Joint Undertaking (101112153)
research agreement between Bristol-Myers Squibb and icometrix
ITEA grant from Flanders Innovation and Entrepreneurship. (20030 HeKDisco, HBC.2021.0500)
ITEA grant from Flanders Innovation and Entrepreneurship. (20030 HeKDisco, HBC.2021.0500)
ITEA grant from Flanders Innovation and Entrepreneurship. (20030 HeKDisco, HBC.2021.0500)
ITEA grant from Flanders Innovation and Entrepreneurship. (20030 HeKDisco, HBC.2021.0500)
ITEA grant from Flanders Innovation and Entrepreneurship. (20030 HeKDisco, HBC.2021.0500)
Fonds Wetenschappelijk Onderzoek (1SD5322N, 12A6U25N, 1805620N)
Fonds Wetenschappelijk Onderzoek (1SD5322N, 12A6U25N, 1805620N)
- License Information
-
More Information
Article History
Received: 2 July 2025
Accepted: 9 April 2026
First Online: 16 May 2026
Declarations
:
: Lars Costers, Rebecca Bartz, Diana Sima, Annemie Ribbens and Dirk Smeets are employees of icometrix. Enrique Alvarez has received compensation for activities such as advisory boards, lectures and consultancy with the following companies and organizations: Biogen, Celgene/BMS, EMD Serono/Merck, Genentech/Roche, Horizon/Amgen, Novartis, Sanofi, Cionic, and TG Therapeutics and research support from: Atara, Biogen, BMS, Genentech/Roche, Novartis, Sanofi, TG Therapeutics, Patient-Centered Outcomes Research Initiative, National Multiple Sclerosis Society, National Institutes of Health, and Rocky Mountain MS Center. Other authors have declared no conflict of interest.
